>
Switch to:

Altamira Therapeutics EV-to-EBIT

: -1.44 (As of Today)
View and export this data going back to 2014. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Altamira Therapeutics's Enterprise Value is $13.07 Mil. Altamira Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 was $-9.10 Mil. Therefore, Altamira Therapeutics's EV-to-EBIT for today is -1.44.

The historical rank and industry rank for Altamira Therapeutics's EV-to-EBIT or its related term are showing as below:

NAS:CYTO' s EV-to-EBIT Range Over the Past 10 Years
Min: -1.58   Med: -0.73   Max: 0.18
Current: -0.98

-1.58
0.18

During the past 10 years, the highest EV-to-EBIT of Altamira Therapeutics was 0.18. The lowest was -1.58. And the median was -0.73.

NAS:CYTO's EV-to-EBIT is ranked lower than
99.99% of the 37 Companies
in the Biotechnology industry.

( Industry Median: 21.16 vs. NAS:CYTO: -0.98 )

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Altamira Therapeutics's Enterprise Value for the quarter that ended in Jun. 2021 was $39.38 Mil. Altamira Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 was $-9.10 Mil. Altamira Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2021 was -23.11%.


Altamira Therapeutics EV-to-EBIT Historical Data

The historical data trend for Altamira Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altamira Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.58 -1.02 -1.18 -0.76 -1.96

Altamira Therapeutics Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.47 -0.76 - -1.96 -

Competitive Comparison

For the Biotechnology subindustry, Altamira Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Altamira Therapeutics EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, Altamira Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Altamira Therapeutics's EV-to-EBIT falls into.



Altamira Therapeutics EV-to-EBIT Calculation

Altamira Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=13.072/-9.1017559657812
=-1.44

Altamira Therapeutics's current Enterprise Value is $13.07 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Altamira Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 was $-9.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Altamira Therapeutics  (NAS:CYTO) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Altamira Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2021 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2021 ) =EBIT / Enterprise Value (Q: Jun. 2021 )
=-9.1017559657812/39.37892273915
=-23.11 %

Altamira Therapeutics's Enterprise Value for the quarter that ended in Jun. 2021 was $39.38 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Altamira Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 was $-9.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Altamira Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Altamira Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Altamira Therapeutics Business Description

Altamira Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2834
Traded in Other Exchanges
Address
8 The Green, Suite 12455, Dover, DE, USA, 19901
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)